Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-PSMA-TGFβRDN Cells in Advanced Castrate Resistant Prostate Cancer
NCT03089203Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Mar 2017
- Primary completion
- Sep 2038
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART-PSMA-TGFβRDN in prostate cancer (PCa) (5 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Occurrence of study related adverse events, laboratory toxicities and clinical events at 15 years, Clinical feasibility defined as frequency of subjects enrolled who do not receive CART-PSMA-TGFβRDN cells at 30 days and 1 more. Started Mar 2017; status: active, not recruiting.
02
Drugs
CART-PSMA-TGFβRDN
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03089203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089203.